Understanding Opportunistic Infections in HIV/AIDS

Every year, thousands of people living with HIV in India do not die from the virus itself – they die from infections that a healthy immune system would ordinarily handle without difficulty. These are called opportunistic infections (OIs), and understanding them is central to understanding why HIV/AIDS is so dangerous, and what can be done about it. For law students and public health advocates, grasping this medical reality is essential to appreciating why access to treatment and protection of rights under legislation like the HIV and AIDS (Prevention and Control) Act, 2017 is not just a legal formality – it is a matter of life and death.

What are opportunistic infections? 🔗

Opportunistic infections are infections that occur more frequently and are more severe in people with weakened immune systems, including people with HIV. The word “opportunistic” captures the core idea: these pathogens seize the opportunity created by a compromised immune system. In a healthy person, bacteria, fungi, viruses, and parasites that are present in the environment – or even in the body itself – are kept in check by a functioning immune system. In a person living with HIV who is not receiving treatment, this protective shield gradually breaks down.

HIV targets CD4+ T-lymphocytes, and as these immune cells decline, the body becomes increasingly unable to fight off pathogens that rarely cause disease in immunocompetent people. The critical threshold is a CD4 count below 200 cells/mm³ – below this level, the risk of OIs increases sharply. Many OIs are formally classified as AIDS-defining conditions, meaning their presence in an HIV-positive person confirms a diagnosis of AIDS, the most advanced stage of the infection, regardless of the CD4 count.

Why OIs matter in the Indian context 🔗

India carries one of the largest HIV burdens in the world, and the pattern of opportunistic infections here differs significantly from high-income countries. India’s National AIDS Control Programme (NACP), implemented by the National AIDS Control Organisation (NACO) under the Ministry of Health and Family Welfare, has evolved over four phases to provide prevention, testing, and treatment services nationwide. Despite this progress, OIs remain a primary driver of illness and death among people living with HIV (PLHIV) in India, particularly among those who are diagnosed late or who struggle to access antiretroviral therapy (ART).

A prospective cohort study from a tertiary care centre in western India found that out of 223 people living with HIV, 43.5% developed at least one opportunistic infection during the follow-up period, with tuberculosis, candidiasis, and non-tuberculous mycobacterial infections being the most frequent. This data underscores the scale of the challenge and the need for early screening, prophylaxis, and consistent ART adherence.

Common opportunistic infections in HIV/AIDS patients 🔗

Tuberculosis (TB) 🔗

Tuberculosis is by far the most dominant OI affecting PLHIV in India. A prospective study from Pune found TB to be the most common OI, with an incidence of 15.4 per 100 person-years among HIV-infected individuals. In hospital settings in north India, TB accounted for 71% of all OIs among hospitalised HIV-infected patients, making it the most common cause of death in this group.

TB and HIV form a particularly lethal combination. HIV weakens the immunity needed to control Mycobacterium tuberculosis, while TB accelerates HIV progression by activating the immune system in ways that promote viral replication. The infection can affect not just the lungs but also the kidneys, brain, lymph nodes, and skin. In India, TB-HIV co-infection has prompted a collaboration between NACO and the Revised National TB Control Programme (RNTCP), implementing what are called the “Three I’s” – intensified TB case finding, isoniazid preventive therapy, and TB infection control in HIV care settings.

Pneumocystis jirovecii pneumonia (PJP) 🔗

Formerly known as Pneumocystis carinii pneumonia (PCP), this lung infection caused by the fungus Pneumocystis jirovecii was one of the defining features of the early AIDS epidemic globally. PJP is considered an AIDS-defining condition – its presence in an HIV-positive patient signals progression to AIDS. It typically presents with a persistent dry cough, progressive breathlessness on exertion, and fatigue developing over days to a few weeks – a presentation different from TB, which evolves more slowly over months.

In India, PJP is less prevalent than in Western countries, partly due to differences in pathogen prevalence and immune exposure patterns, but it still represents a significant cause of respiratory illness in patients with advanced immunosuppression, particularly those with CD4 counts below 200 cells/mm³.

Oral and oesophageal candidiasis 🔗

Candida species, particularly Candida albicans, naturally colonise the mouth and gastrointestinal tract. In immunocompetent individuals, this causes no disease. In PLHIV with declining CD4 counts, the fungus proliferates into a clinical infection. Among HIV-infected individuals in Pune, oral candidiasis had an incidence of 11.3 per 100 person-years, making it the second most common OI after TB. Oral thrush – white, curd-like patches on the tongue or inner cheeks – is often one of the earliest visible signs that an HIV-positive person’s immunity is deteriorating. When the infection spreads to the oesophagus, it causes painful swallowing and is classified as an AIDS-defining illness.

Herpes zoster 🔗

Herpes zoster, commonly called shingles, is caused by the reactivation of the varicella-zoster virus (VZV) – the same virus that causes chickenpox. In immunocompetent individuals, the virus stays dormant in sensory nerve ganglia after a childhood chickenpox infection. When immunity weakens – as it does with HIV – the virus can reactivate, producing a painful blistering rash that follows a specific nerve pathway (dermatome).

In the same Pune cohort, herpes zoster had an incidence of 10.1 per 100 person-years, making it the third most common OI. What makes herpes zoster particularly significant in HIV patients is how differently it behaves. In immunocompromised individuals, including those with HIV, herpes zoster can present in an extensive form involving multiple dermatomes or even as a disseminated infection, unlike the typically self-limiting single-dermatome presentation in healthy individuals. A study from Karnataka found that 37.77% of patients with herpes zoster were HIV-positive, and 64.7% of these HIV-seropositive herpes zoster patients were in the 21-40 age group – a stark departure from the usual demographic of older adults.

Importantly, herpes zoster constitutes WHO Clinical Stage 2 of HIV infection, meaning its occurrence in a young adult should trigger an immediate HIV test. Complications can include post-herpetic neuralgia (persistent nerve pain long after the rash resolves), herpes zoster ophthalmicus (affecting the eye and potentially causing vision loss), and in the most severe cases, progressive outer retinal necrosis in patients with very low CD4 counts.

Cryptococcal meningitis 🔗

Cryptococcus neoformans, a fungus found in soil and bird droppings, causes a severe infection of the brain’s lining (meningitis) in people with advanced immunosuppression. It is one of the most dangerous OIs, with high mortality if not promptly treated. Among people living with HIV in South India, cryptococcal meningitis was found in 16% of study participants, highlighting its continued relevance in the Indian clinical setting.

Toxoplasmosis 🔗

Toxoplasma gondii, a parasite often acquired through contact with cat faeces or undercooked meat, causes cerebral toxoplasmosis in PLHIV with severely depleted immunity. It presents with headache, fever, confusion, and seizures. Cerebral toxoplasmosis affected 13.5% of HIV-positive patients in a South Indian hospital study, and like cryptococcal meningitis, it is an AIDS-defining condition.

Malaria 🔗

In countries like India, where malaria is endemic, the interaction between HIV and malaria deserves special attention. A weakened immune system means that PLHIV are more susceptible to malaria infection, experience more severe episodes, and are at greater risk of complications like cerebral malaria. Conversely, malaria infection triggers immune activation that can accelerate HIV replication. People with HIV travelling to or residing in areas with high malaria transmission may require preventive antimalarial medication as a standard precaution.

The CD4 count-OI relationship 🔗

Understanding which OIs emerge at which level of immunosuppression is clinically and legally important – it helps determine when preventive treatment (prophylaxis) should begin. As a general guide:

At CD4 counts below 500 cells/mm³, some OIs like herpes zoster begin to appear. At counts below 200 cells/mm³, the risk expands significantly to include PJP, TB dissemination, and cryptococcal meningitis. At counts below 100 cells/mm³, the most severe infections including cytomegalovirus (CMV) retinitis and toxoplasmosis become more likely. This staged relationship is why HIV medicines prevent HIV from damaging the immune system and are critical to preventing OIs before they occur.

Prevention and treatment of opportunistic infections 🔗

Antiretroviral therapy (ART) as the foundation 🔗

The single most effective intervention to prevent OIs is maintaining a suppressed viral load through consistent ART. When HIV replication is controlled, CD4 counts recover, and the immune system regains enough strength to fend off opportunistic pathogens. OIs are far less common today than in the early AIDS era precisely because of the availability of effective antiretroviral treatment. In India, free ART has been available under NACP since April 2004. The 2021 National Operational Guidelines for ART Services include detailed protocols for managing opportunistic infections and co-morbidities as part of comprehensive HIV care.

Cotrimoxazole preventive therapy (CPT) 🔗

One of the most cost-effective preventive interventions is cotrimoxazole (trimethoprim-sulfamethoxazole), a widely available antibiotic that provides prophylaxis against PJP, toxoplasmosis, and some bacterial infections. NACO guidelines recommend CPT for all PLHIV with CD4 counts below 350 cells/mm³. This single affordable drug has prevented countless deaths across resource-limited settings.

Treatment of specific OIs 🔗

OI treatment depends on the specific pathogen involved – antiviral, antibiotic, antifungal, and antiparasitic drugs are used as appropriate. TB is treated with standard multi-drug regimens. Candidiasis responds to fluconazole. Herpes zoster is managed with antiviral drugs such as acyclovir or valacyclovir, which reduce the severity and duration of the outbreak. Cryptococcal meningitis requires amphotericin B, a more intensive treatment. An important complication of treating OIs while initiating ART is immune reconstitution inflammatory syndrome (IRIS), where a recovering immune system overreacts to existing pathogens, temporarily worsening symptoms. Clinicians must account for this when sequencing OI treatment with ART initiation.

The public health and legal dimension 🔗

OIs are not just a clinical issue – they have direct public health consequences. Tuberculosis, for instance, is airborne and contagious. An HIV-positive person with undiagnosed or untreated TB can transmit the bacteria to others, making TB-HIV co-infection a dual threat to community health. This is precisely why NACO’s policies include extensive guidelines on the management of OIs as part of India’s national HIV response – controlling OIs in PLHIV is inseparable from controlling HIV-related morbidity and infectious disease transmission at the population level.

Legally, the HIV and AIDS (Prevention and Control) Act, 2017 mandates that diagnostic facilities for OI management be made accessible to PLHIV. Denial of such services – whether by a hospital, employer, or public institution – constitutes a violation of rights under this Act. This places OI treatment squarely within the domain of rights-based healthcare, not merely a medical convenience.

For someone living with HIV who cannot access consistent ART or OI prophylaxis due to stigma, financial barriers, or systemic neglect, the medical consequences are predictable and severe. Understanding opportunistic infections is thus a foundational element for anyone working in health law, advocacy, or public policy – because no legal protection means much if the person it protects is denied the treatment that keeps them alive.

What do you think? If a person living with HIV is denied treatment for an opportunistic infection by a healthcare provider on discriminatory grounds, what legal remedies should be available under Indian law – and are existing mechanisms strong enough to enforce them? Also, given that TB spread from an untreated HIV-positive patient can infect others in the community, how should the law balance individual privacy rights with the collective public health interest?

References

1. https://naco.gov.in/hiv-aids-p-c-act-2017
2. https://www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/opportunistic-infections
3. https://www.ncbi.nlm.nih.gov/books/NBK539787/
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC5337408/
5. https://pubmed.ncbi.nlm.nih.gov/41565985/
6. https://pubmed.ncbi.nlm.nih.gov/18602329/
7. https://pubmed.ncbi.nlm.nih.gov/15555069/
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC5389218/
9. https://pubmed.ncbi.nlm.nih.gov/22233739/
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC4545828/
11. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/what-opportunistic-infection
12. https://www.usacs.org.in/pdfs/artguideline2.pdf
13. https://naco.gov.in/about-us/policies-guidelines